Omeprazol Krka (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Krka, is a Proton Pump Inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to manage gastro‑intestinal reflux disease and related conditions in adults.

GNH USA supplies Omeprazol Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazol Krka is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related gastrointestinal conditions: - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of esophageal erosion. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid production. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates. - NSAID‑induced ulcer prophylaxis: lowers risk of ulcer development in high‑risk patients.

Adverse reactions to Omeprazole may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Headache: mild, transient headache reported in clinical use. - Diarrhea: loose stools occurring early in treatment. - Abdominal pain: mild discomfort or cramping. - Nausea: occasional feeling of queasiness. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis linked to altered gut flora. - Acute interstitial nephritis: sudden kidney inflammation. - Hypomagnesemia: low serum magnesium with prolonged use. - Stevens‑Johnson syndrome: rare severe skin reaction. - Fracture risk: increased risk of hip, wrist or spine fractures with long‑term use. - Liver enzyme elevation: raised ALT/AST levels indicating hepatic stress.

When prescribing Omeprazole, clinicians should consider several safety aspects: - Assess renal function: adjust use in patients with severe kidney impairment. - Evaluate liver status: use cautiously in hepatic disease. - Review concomitant medications: potential for drug‑drug interactions. - Monitor long‑term use: consider step‑down therapy after symptom control. - Pregnancy and lactation: weigh benefits against potential risks. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs. Awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular events. - Atazanavir: decreased absorption, loss of antiviral efficacy. - Dasatinib: lowered plasma concentrations, reduced therapeutic effect.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, monitor coagulation parameters. - Phenytoin: decreased serum levels, watch for seizure control. - Digoxin: possible rise in serum digoxin, check levels periodically.